Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 289

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers

Open access
Steffin, David, Ghatwai, Nisha, Montalbano, Antonino, Rathi, Purva, Courtney, Amy N., Arnett, Azlann B., Fleurence, Julien, Sweidan, Ramy, Wang, Tao, Zhang, Huimin, Masand, Prakash, Maris, John M., Martinez, Daniel, Pogoriler, Jennifer, Varadarajan, Navin, Thakkar, Sachin G., Lyon, Deborah, Lapteva, Natalia, Zhuyong, Mei, Patel, Kalyani, Lopez-Terrada, Dolores, Ramos, Carlos A., Lulla, Premal, Armaghany, Tannaz, Grilley, Bambi J., Gottschalk, Stephen, Dotti, Gianpietro, Metelitsa, Leonid S., Heslop, Helen E., Brenner, Malcolm K., Sumazin, Pavel, Heczey, Andras·2025·Nature

Abstract

Interleukin-15 (IL-15) promotes the survival of T lymphocytes and enhances the antitumour properties of chimeric antigen receptor (CAR) T cells in preclinical models of solid neoplasms in which CAR T cells have limited efficacy1, 2, 3–4. Glypican-3 (GPC3) is expressed in a group of solid cancers5, 6, 7, 8, 9–10, and here we report the evaluation in humans of the effects of IL-15 co-expression on GPC3-expressing CAR T cells (hereafter GPC3 CAR T cells). Cohort 1 patients (NCT02905188 and NCT02932956) received GPC3 CAR T cells, which were safe but produced no objective antitumour responses and reached peak expansion at 2 weeks. Cohort 2 patients (NCT05103631 and NCT04377932) received GPC3 CAR T cells that co-expressed IL-15 (15.CAR), which mediated significantly increased cell expansion and induced a disease control rate of 66% and antitumour response rate of 33%. Infusion of 15.CAR T cells was associated with increased incidence of cytokine release syndrome, which was controlled with IL-1/IL-6 blockade or rapidly ameliorated by activation of the inducible caspase 9 safety switch. Compared with non-responders, tumour-infiltrating 15.CAR T cells from responders showed repression of SWI/SNF epigenetic regulators and upregulation of FOS and JUN family members, as well as of genes related to type I interferon signalling. Collectively, these results demonstrate that IL-15 increases the expansion, intratumoural survival and antitumour activity of GPC3 CAR T cells in patients. We evaluate the effects in humans of interleukin-15 co-expression on glypican-3 (GPC3) chimeric antigen receptor (CAR) T cells and demonstrate that IL-15 increases the expansion, intratumoural survival and antitumour activity of GPC3 (expressed in a group of solid cancers) CAR T cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-024-08261-8

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 45 references

Cited by

See all 289

Metadata

Authors
Steffin, D., Ghatwai, N., Montalbano, A., Rathi, P., Courtney, A. N., Arnett, A. B., Fleurence, J., Sweidan, R., Wang, T., Zhang, H., Masand, P., Maris, J. M., Martinez, D., Pogoriler, J., Varadarajan, N., Thakkar, S. G., Lyon, D., Lapteva, N., Zhuyong, M., Patel, K., Lopez-Terrada, D., Ramos, C. A., Lulla, P., Armaghany, T., Grilley, B. J., Gottschalk, S., Dotti, G., Metelitsa, L. S., Heslop, H. E., Brenner, M. K., Sumazin, P., & Heczey, A.
Venue
Nature
Published
2024-11-27
Volume
637
Issue
8047
Pages
940-946
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4404754574
Cited by
289
References
45
FWCI
44.35
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. https://app.cochat.ai/papers/10.1038/s41586-024-08261-8
The paper
Steffin, D., Ghatwai, N., Montalbano, A., Rathi, P., Courtney, A. N., Arnett, A. B., Fleurence, J., Sweidan, R., Wang, T., Zhang, H., Masand, P., Maris, J. M., Martinez, D., Pogoriler, J., Varadarajan, N., Thakkar, S. G., Lyon, D., Lapteva, N., Zhuyong, M., . . . Heczey, A. (2025). Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. https://doi.org/10.1038/s41586-024-08261-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.